News – Nordic medac Urology Grant
22.01.2021
Medac´s intention with this grant is to support Nordic resident physicians and/or specialists within urology with interest in research and development.
Press Release – medac Diagnostics: a complete package for COVID-19 testing
08.05.2020
With immediate effect: 3 million proven antibody tests for SARS-CoV-2 and mastermix ready-to use PCR tests. 17 million more antibody tests available.
Press Release – medac Diagnostics Portfolio
08.05.2020
With immediate effect: medac´s proven methods for SARS-CoV-2 testing for the German-speaking world
Medac statement regarding the coronavirus COVID-19:
25.3.2020
At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply shortages for our medicinal products because of the coronavirus COVID-19.
We support this by a prevention program and our purchasing and production strategy:
- medac has prepared itself carefully to protect employees and supply chain,
- medac operates its own production sites in Central Europe and the goods transport within Europe is not limited up to now,
- generally, medac has more than one supplier for the intermediate products used for its medicinal products,
- medac has sufficient stocks of all intermediate products so that supply fluctuations will not cause immediate shortages.
Press release – First marketing authorisation worldwide for methotrexate in moderate psoriasis
Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time.
Click here to view full Press release
Press release – Results of phase III study with Treosulfan, EMA approval pending
Highly effective with reduced toxicity – Treosulfan-based regimen is a promising new conditioning therapy for MDS
and AML
Click here to view full Press release
Press release – Medac Finland – 10-years anniversary symposium
Enhancing the potential of methotrexate.
Optimise rheumatism treatment in Finland with Metoject® PEN and ensure long-term success of therapy
Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the potential of methotrexate as initial treatment and follows the European treatment guidelines in a slightly adopted way focusing on combination therapy: “At baseline, 68 % used methotrexate-based combination therapy, and 31 % used triple therapy with methotrexate, hydroxychloroquine, and sulphasalazine (the Fin-RACo regimen)”.
Press release – Medac at the EADV 2017
Methotrexate for psoriasis: effective, safe, favourable.
Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva.
Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no wonder that recent treatment recommendations consider MTX as first-line and cost-effective therapeutic for the systemic treatment of psoriasis. And still the potential of MTX is often not fully exploited. In particular the dose and route of administration are aspects that should be considered.
Write personal the names of each living thing in the appropriate box.
Press release – Medac at DGRh 2017
Enhancing the potential of methotrexate.
Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy
Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate as initial treatment and follows the treatment guidelines closely: “After 3 months, 82 % of patients with a diagnosis of RA were given first line treatment with methotrexate. […] In 78 % of the patients treated with methotrexate, the starting dose was 15 mg weekly”. Long-term data from the core documentation also confirm at 61 % the great importance of MTX in the treatment of RA. Current data from a German health insurance, however, paint a dramatically different picture nationwide. Given that csDMARDS account for 35 % of drug treatment, Germany is some way from appropriate therapeutic treatment of patients with rheumatoid arthritis.
The symposium on methotrexate sponsored by Medac at the DGRh congress in Stuttgart addressed this issue. As well as a new research project on the actual medical treatment situation, various options for improving the first line therapy with MTX were revealed.
Click here to view full Press release
Press Release – medac at the BAD meeting 2017
Update on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended
- British Association of Dermatologists’ guidelines reaffirms the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis
- Recently in The Lancet published METOP trial meets the need of high-quality clinical trial with methotrexate in long-term therapy and shows lasting efficacy and safety of subcutaneous methotrexate over one year in an intensified dosing schedule
Click here to view full Press Release
